Sponsor:
Rutgers, The State University of New Jersey
Code:
NCT07402473
Conditions
HER2-positive Early-stage Breast Cancer
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Not accepted
Interventions
Trastuzumab
Pertuzumab
Docetaxel
Carboplatin
Study Details
Eligibility Criteria
Study Design
Interventions and Outcome Measures
Central Contacts and Locations
More Information
Trial information was received from ClinicalTrials.gov and was last updated on 2026-04-25. This information was provided to ClinicalTrials.gov by Rutgers, The State University of New Jersey on 2026-04-23.